- $13.77m
- -$26.50m
- $43.95m
Hookipa Pharma Inc Expected To Post A Loss Of 36 Cents A Share: Earnings Preview
U.S. STOCKS ON THE MOVE-ToughBuilt Industries Inc, Koss Corp, Centene Corp
FDA allows Hookipa to begin human trial of prostate cancer drug
U.S. STOCKS ON THE MOVE-Lakeland Financial, World Wrestling Entertainment, Bank of Marin
FDA allows Hookipa to begin human trial on prostate cancer drug, shares fall
Brief: FDA Accepts Hookipa's Investigational New Drug Application For HB-300 For Treatment Of Metastatic Castration-Resistant Prostate Cancer
Brief: HOOKIPA Pharma Files For Mixed Shelf Offering Of Up To $200 Mln
Brief: HOOKIPA Pharma Inc Files Prospectus Relates To Proposed Resale Or Other Disposition By Selling Stockholder Of Up To 1.67 Million Shares Of Common Stock
Brief: Hookipa Pharma Entered Registration Rights Agreement With Gilead Sciences
Brief: Hookipa Announces Positive Phase 1, 2 Plans For HB-200 Program For Treatment Of Advanced Head And Neck Cancers
Brief: Hookipa To Present Complete Hb-200 Phase 1 Results
Hookipa Pharma Inc Reports Results For The Quarter Ended In March: Earnings Summary
Brief: HOOKIPA Pharma Reports First Quarter 2022 Financial Results, Recent Highlights
Hookipa Pharma Inc Expected To Post A Loss Of 24 Cents A Share: Earnings Preview
Hookipa Pharma Inc Expected To Post A Loss Of 24 Cents A Share: Earnings Preview
HOOKIPA Pharma up on immunotherapies preclinical data
NASDAQ RESUMED AT 11:06 AM
Brief: New Data Show Hookipa’S Arenaviral Immunotherapies Induce Potent T Cell Responses In Novel Combinations And Against Tumor Self-Antigens
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:01 AM